Press releaseGlobe Newswire
Cellectar Biosciences
CLRB · NASDAQ
$1.23+$0.11 (+9.82%)TodayMarket closed ·
Prev close $1.12
Latest news
- Press releaseGlobe Newswire
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
- NewsTim Melvin
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
- News
Cellectar Biosciences Q2 2026 Earnings Call Transcript
- Press releaseGlobe Newswire
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- Press releaseGlobe Newswire
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
- Press releaseGlobe Newswire
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
- News
Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call
- Press releaseGlobe Newswire
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- News
Earnings Scheduled For May 14, 2026
- NewsVandana Singh
What's Going With Cellectar Biosciences Stock On Wednesday?
- NewsAvi Kapoor
Crude Oil Down 4%; PayPal Shares Fall After Q1 Results
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Dow Jumps Over 300 Points; Pfizer Posts Upbeat Earnings
- NewsVandana Singh
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
Market-Moving news for May 5th
- News
Cellectar Biosciences Phase 2b CLOVER WaM 12-Month Data Shows 83.6% ORR And Durable Responses Exceeding 18 Months In Post-BTKi Patients
- Press releaseGlobe Newswire
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
- Press releaseGlobe Newswire
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
- Press releaseGlobe Newswire
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
- Press releaseGlobe Newswire
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
- Press releaseGlobe Newswire
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
- News
Earnings Scheduled For March 4, 2026
- News
Insights into Cellectar Biosciences's Upcoming Earnings
- Press releaseGlobe Newswire
Cellectar Biosciences Expands Global Intellectual Property Estate
- NewsAvi Kapoor
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
- Press releaseGlobe Newswire
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
- Press releaseGlobe Newswire
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- News
Earnings Outlook For Cellectar Biosciences
- Press releaseGlobe Newswire
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
- Press releaseGlobe Newswire
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
- Press releaseGlobe Newswire
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
- Press releaseGlobe Newswire
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
- Press releaseGlobe Newswire
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
- Press releaseGlobe Newswire
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
- Press releaseGlobe Newswire
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.